Last mentioned: Mar 18, 2026
Anticipated Regulatory Milestones
Potential for further regulatory filings based on ongoing Phase 3 data.
AACR Annual Meeting
Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.
AACR Presentation Announcement
Zymeworks confirms multiple data sessions for Ziihera at the upcoming annual meeting.
Presentation Announcement
Zymeworks announces multiple abstracts accepted for AACR 2026.
Regulatory Progress
Advancement of Biologics License Application (BLA) filings for lead indications.
ASCO Data Release
Positive pivotal Phase 2 results in biliary tract cancer (BTC) showcased at ASCO.
Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
Zymeworks Inc. has announced a series of clinical and preclinical presentations for its lead asset, Ziihera® (zanidatamab-hrii), at the 2026 AACR Annual Meeting. The data will highlight the therapeutic potential of this HER2-targeted bispecific antibody across multiple oncology indications.
Emerging research indicates that specific non-psychoactive cannabis compounds, particularly THCV, may reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This breakthrough offers a potential pharmaceutical path for a condition that currently affects nearly 33% of the global adult population.